MARKET

CRDF

CRDF

Cardiff Oncology Inc
NASDAQ
4.135
+0.065
+1.60%
Opening 15:51 07/14 EDT
OPEN
4.070
PREV CLOSE
4.070
HIGH
4.150
LOW
4.065
VOLUME
634.89K
TURNOVER
--
52 WEEK HIGH
5.64
52 WEEK LOW
2.010
MARKET CAP
275.08M
P/E (TTM)
-4.4201
1D
5D
1M
3M
1Y
5Y
1D
Largest borrow rate increases among liquid names
TipRanks · 18h ago
Weekly Report: what happened at CRDF last week (0707-0711)?
Weekly Report · 19h ago
Cardiff Oncology (CRDF) Initiated with a Buy at Ladenburg Thalmann & Co.
TipRanks · 4d ago
Cardiff Oncology Inc. Files Initial Statement of Beneficial Ownership for Roger Sidhu, Chief Medical Officer
Reuters · 6d ago
Cardiff Oncology Price Target Announced at $19.00/Share by Ladenburg Thalmann
Dow Jones · 6d ago
Ladenburg Thalmann Initiates Coverage On Cardiff Oncology with Buy Rating, Announces Price Target of $19
Benzinga · 6d ago
GLOBAL ONCOLOGY BREAKTHROUGHS BEING FUELED BY ADVANCEMENTS IN CLINICAL TRIALS AND NEW THERAPIES
Reuters · 6d ago
Largest borrow rate increases among liquid names
TipRanks · 6d ago
More
About CRDF
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.

Webull offers Cardiff Oncology Inc stock information, including NASDAQ: CRDF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRDF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRDF stock methods without spending real money on the virtual paper trading platform.